Complete Guide to semaglutide Pharmacokinetics
Overview
semaglutide is a GLP-1 Receptor Agonist used in the Obesity / Weight Management therapeutic area. It is indicated for Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes. Interactive semaglutide (Wegovy®/Ozempic®) population PK/PD simulator predicting individual weight loss over 68 weeks by dose escalation schedule, body weight, sex, T2D status, HbA1c, and age. Based on Strathe et al. 2023 STEP trials model (n=2,580).
Mechanism of Action
semaglutide exerts its pharmacological effect by targeting GLP-1 Receptor. As a GLP-1 Receptor Agonist, it modulates this target to achieve therapeutic efficacy in Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Population PK/PD (1-CMT + Emax/Indirect Response) models for semaglutide:
| Parameter | Value |
|---|---|
| ka | 0.018 |
| V/F | 12.5 |
| CL/F | 0.064 |
| EC50 | 0.98 |
| t1/2 | 135 |
| Emax (direct) | -7.2 |
| Emax (indirect) | -14.8 |
| T2D effect on Emax | 0.68 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
semaglutide is administered via the Subcutaneous route. Subcutaneous administration provides sustained absorption from the injection site. Bioavailability and absorption rate may vary by injection site and volume.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Obesity / Weight Management therapeutic area, for the treatment of Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes, understanding the pharmacokinetics of semaglutide is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect semaglutide pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive semaglutide PK Simulator
Explore semaglutide pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of semaglutide?
The elimination half-life of semaglutide depends on patient-specific factors. Use our interactive semaglutide PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is semaglutide administered?
semaglutide is administered via the Subcutaneous route. It is indicated for Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes. As a GLP-1 Receptor Agonist, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of semaglutide?
Key pharmacokinetic parameters for semaglutide include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate semaglutide dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive semaglutide PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.